A study conducted at the Ichilov-Tel Aviv Medical Center showed promising results in the treatment of pectasol in prostate cancer patients in the case of recurrence of non-metastatic disease. Factol is a natural substance that inhibits the protein galactin 3, which is involved in the tumor process and in the recurrence of prostate cancer. “Prostate cancer is the most common tumor in men in the Western world, with a third of patients showing recurrence after initial treatment with surgery or radiation. When recurrence is manifested by an increase in the PSA marker without metastases – there is currently no proven treatment.” For the course of the disease without treatment in which the majority of patients (about 80%) show a worsening of the disease indices within six months, it has now been proven that the treatment with factsol led to a stabilization of the disease by 78% (only 22% showed disease progression).
The results of the study were recently published in the journal NUTRIENTS and it is soon planned to start a larger study – Phase 3.
Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here